Spotlight on SynaptixBio – A Virtual Approach to Developing an Oligonucleotide Therapy for a CNS Disorder

Time: 2:30 pm
day: Day One


  • TUBB4A Leukodystrophy and it’s suitability for an oligonucleotide therapeutic approach
  • SynaptixBio’s virtual strategy to outsourcing and developing a therapeutic
  • Exploring the pros and cons of applying a virtual model to development – learnings from a start-up biotechnology company